Xi Venture Capital and Qirui Pharmaceutical have completed nearly RMB 200 million in Series B+financing

　　Recently, Hope Medicine Inc. (hereinafter referred to as "Heqirui") announced the completion of a B+round financing of nearly 200 million yuan, led by Xi Venture Capital and Dingpei Group. This round of financing will provide strong support for the core pipeline of Heqirui, the two international clinical phase II studies being conducted on HMI-115 monoclonal antibody, and the development of other product lines of the company.

　　There are significant unmet clinical needs in the field of hair loss and women's health, and Xi Venture Capital has been focusing on this biopharmaceutical niche. As an important strategic investor of Qirui, Xicheng Venture Capital will provide continuous and professional support in various aspects such as funding and industry empowerment, and actively promote collaborative cooperation with the Wuxi sector, landing in Wuxi with pipelines such as Qirui MG53.

　　Heqirui Pharmaceutical is a science driven clinical stage innovative biopharmaceutical company. The company was founded based on the in-depth understanding and decades of research achievements in the field of translational medicine by Professor Xiao Ruiping, Dean of the School of Future Technology at Peking University, and his team. Based on excellent scientific research and with the goal of improving quality of life, it is committed to researching, developing, and commercializing innovative new drugs for common and major diseases that threaten human health.

　　At present, under a global exclusive license agreement signed with Bayer for the development and industrialization of monoclonal antibody HMI-115 targeting prolactin receptors, Sinopharm is conducting the development and industrialization of multiple indications worldwide. It is reported that the global phase II clinical trial of HMI-115 is currently underway for two indications: endometriosis and androgenetic alopecia. In addition to HMI-115, based on Professor Xiao Ruiping's breakthrough research on MG53 and its mechanism of action at the Institute of Molecular Medicine, School of Future Technology, Peking University, and his introduction of MG53, a protein drug targeting a novel target, from Peking University.

　　Xi Venture Capital is a state-owned venture capital institution that integrates seed, angel, entrepreneurship, equity, mergers and acquisitions, and S funds. The company has established a fund system covering the entire life cycle of enterprises, managing a total fund size of over 240 billion yuan, and providing comprehensive support to enterprises that are in line with their development stages. Xi Venture Capital has currently established a specialized and diversified biopharmaceutical investment team, with layouts in innovative drugs, biotechnology, medical devices, and other fields. It has invested in enterprises with leading domestic technology advantages in multiple sub fields such as Jianshi Medical, Jushu Biotechnology, Ruiyue Biotechnology, and Xiantong Pharmaceutical.